| |
No. (%)
|
|---|
|
Age (years)
|
|
Median
|
50.5 (IQR 41–57)
|
|
Gender
|
|
Male
|
9 (69.2)
|
|
Female
|
4 (30.8)
|
|
ECOG PS
|
|
One
|
9 (69.2)
|
|
Two
|
4 (30.8)
|
|
Sidedness of the primary tumor
|
|
Right
|
3 (23.1)
|
|
Left
|
10 (76.9)
|
|
Number of organs involved
|
|
Median
|
1
|
|
Range
|
(1–2)
|
|
One
|
8 (61.5)
|
|
Greater than one
|
5 (38.5)
|
|
Site of metastasis
|
|
Liver
|
5 (38.5)
|
|
Lung
|
1 (7.7)
|
|
LNs
|
6 (46.2)
|
|
Peritoneum
|
5 (38.5)
|
|
KRAS gene mutation
|
|
Mutant
|
7 (53.8)
|
|
Wild-type
|
5 (38.5)
|
|
Unknown
|
1 (7.7)
|
|
Best response to XELOXIRI/A
|
|
CR
|
1 (7.7)
|
|
PR
|
10 (76.9)
|
|
SD
|
2 (15.4)
|
|
Surgical resection margin
| |
|
R0
|
10 (76.9)
|
|
R1
|
3 (23.1)
|
- IQR interquartile range; XELOXIRI/A xeloda, oxaliplatin, irinotecan, and avastin; ECOGPS Eastern Cooperative Oncology Group Performance Status; CR complete response; PR partial response; SD stable disease; Primary primary tumor resection
